umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
N-aryl 2-aryloxyacetamides as a new class of fatty acid amide hydrolase (FAAH) inhibitors
Umeå University, Faculty of Science and Technology, Department of Chemistry.
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience.
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience.
Umeå University, Faculty of Science and Technology, Department of Chemistry.
Show others and affiliations
2017 (English)In: Journal of enzyme inhibition and medicinal chemistry (Print), ISSN 1475-6366, E-ISSN 1475-6374, Vol. 32, no 1, 513-521 p.Article in journal (Refereed) Published
Abstract [en]

Fatty acid amide hydrolase (FAAH) is a promising target for the development of drugs to treat neurological diseases. In search of new FAAH inhibitors, we identified 2-(4-cyclohexylphenoxy)-N-(3-(oxazolo[4,5-b] pyri-din-2-yl) phenyl) acetamide, 4g, with an IC50 of 2.6 mu M as a chemical starting point for the development of potent FAAH inhibitors. Preliminary hit-to-lead optimisation resulted in 2-(4-phenylphenoxy)-N-(3-(oxazolo[4,5-b] pyridin-2-yl)phenyl) acetamide, 4i, with an IC50 of 0.35 mu M.

Place, publisher, year, edition, pages
2017. Vol. 32, no 1, 513-521 p.
Keyword [en]
Fatty acid amide hydrolase inhibitors, endocannabinoid system, oxazolo[4, 5-b]pyridine anilines, 1H- idazo[4, 5-b]pyridine anilines
National Category
Medicinal Chemistry Neurosciences
Identifiers
URN: urn:nbn:se:umu:diva-131874DOI: 10.1080/14756366.2016.1265520ISI: 000392591100045PubMedID: 28114819OAI: oai:DiVA.org:umu-131874DiVA: diva2:1076970
Available from: 2017-02-24 Created: 2017-02-24 Last updated: 2017-02-24Bibliographically approved

Open Access in DiVA

fulltext(2583 kB)38 downloads
File information
File name FULLTEXT01.pdfFile size 2583 kBChecksum SHA-512
6eeadf70392620d881b86f7324a5df791434b92c7bc9e10a00550c3aabcdce835f68d44895996c93e67efcb938e38d4b8394171dbe8ffb8d3f558bb342cdfb65
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Sunduru, NareshSvensson, MonaCipriano, MariateresaMarwaha, SaniaAndersson, David C.Fowler, Christopher J.Elofsson, Mikael
By organisation
Department of ChemistryDepartment of Pharmacology and Clinical Neuroscience
In the same journal
Journal of enzyme inhibition and medicinal chemistry (Print)
Medicinal ChemistryNeurosciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 38 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 93 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf